Blueprint Medicines Reports Q4 2024 Results, $479M AYVAKIT Revenues, EPS $(0.79) Misses Estimates, Stock Falls 8.7%

Blueprint Medicines Corporation ($BPMC) reported its fourth quarter and full year 2024 results, revealing global net product revenues of $479.0 million for AYVAKIT® (avapritinib), including $144.1 million in the fourth quarter. The company reported a GAAP EPS of $(0.79), which missed the estimated $(0.70). However, sales of $146.37 million surpassed the estimate of $145.84 million. Looking ahead, Blueprint Medicines anticipates global AYVAKIT net product revenue to be between $680 million and $710 million in 2025, with peak revenues projected at $4 billion, including $2 billion by 2030. Following the announcement, the company's stock fell by 8.7% in pre-market trading.